Zura Bio (NASDAQ:ZURA) Sees Strong Trading Volume – Here’s Why

Zura Bio Limited (NASDAQ:ZURA) shares saw unusually-strong trading volume on Tuesday . Approximately 703,847 shares changed hands during mid-day trading, a decline of 20% from the previous session’s volume of 877,647 shares.The stock last traded at $6.4050 and had previously closed at $6.30.

Analysts Set New Price Targets

ZURA has been the topic of several research reports. William Blair began coverage on Zura Bio in a research report on Wednesday, July 8th. They issued an “outperform” rating on the stock. Wedbush boosted their price target on Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Guggenheim lifted their target price on shares of Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Monday, July 6th. Finally, Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Zura Bio Price Performance

The firm has a market cap of $618.58 million, a P/E ratio of -5.74 and a beta of -0.02. The firm’s 50-day moving average price is $5.26 and its 200 day moving average price is $5.39.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. Analysts forecast that Zura Bio Limited will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Commodore Capital LP purchased a new position in Zura Bio during the 1st quarter valued at about $19,338,000. Siren L.L.C. lifted its position in shares of Zura Bio by 187.3% in the first quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock worth $22,222,000 after purchasing an additional 2,434,866 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after purchasing an additional 2,052,732 shares in the last quarter. EcoR1 Capital LLC acquired a new stake in shares of Zura Bio during the first quarter worth approximately $7,019,000. Finally, Stempoint Capital LP purchased a new position in Zura Bio during the first quarter valued at approximately $4,483,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.